Wedbush analyst David Nierengarten downgraded Mersana Therapeutics to Neutral from Outperform with a price target of $2, down from $12, after Mersana announced that the UPLIFT clinical trial of upifitamab rilsodotin, or UpRi, did not meet its primary endpoint and the company said it is winding down development efforts with UpRi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRSN:
- Mersana Faces Catastrophe After Test Flub
- Mersana (NASDAQ:MRSN) Nosedives after Ovarian Cancer Trial Disappoints
- Mersana Therapeutics provides strategic reprioritization, financial update
- Mersana Therapeutics’ UPLIFT trial ‘failed to replicate’ previous efficacy data
- Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization